Carcinoid syndrome

临床试验

计划入组 76 人 · 首次发布于 2014 年 2 月 14 日

已完成

NCT01430871

Effects of Serotonin Excess on Bone in Carcinoid Syndrome

计划入组 52 人 · 首次发布于 2011 年 9 月 8 日

尚未招募

PER-049-22

A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome.

计划入组 0 人

药物

查看全部 289 →

Small Molecule

Approved

Telotristat ethyl(Xermelo)

相关疾病：Carcinoid syndrome diarrhea

C₂₇H₂₆ClF₃N₆O₃

Leigh syndrome therapeutic(Leigh syndrome)

ORAI-XXXX

机构

查看全部 12 →

ALPORT SYNDROME FOUNDATION

United States

International Rett Syndrome Foundation

United States

RETT SYNDROME RESEARCH TRUST

United States

资讯

查看全部 3156 →

去年

Crinetics Pharmaceuticals Presents Promising Neuroendocrine Tumor Therapies at NANETS 2024

10个月前

Clinical Evidence Supports Higher Somatostatin Analog Doses for Progressive Neuroendocrine Tumors

去年

临床试验

Telotristat Etiprate for Carcinoid Syndrome Therapy

Effects of Serotonin Excess on Bone in Carcinoid Syndrome

A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome.

药物

Telotristat ethyl(Xermelo)

Leigh syndrome therapeutic(Leigh syndrome)

ORAI-XXXX

机构

ALPORT SYNDROME FOUNDATION

International Rett Syndrome Foundation

RETT SYNDROME RESEARCH TRUST

资讯

Crinetics Pharmaceuticals Presents Promising Neuroendocrine Tumor Therapies at NANETS 2024

Clinical Evidence Supports Higher Somatostatin Analog Doses for Progressive Neuroendocrine Tumors

Teva Pharmaceuticals Launches Generic Octreotide Acetate for Injectable Suspension